Short Interest in Parabilis Medicines, Inc. (NASDAQ:PBLS) Increases By ∞

Parabilis Medicines, Inc. (NASDAQ:PBLSGet Free Report) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 1,116,504 shares, a growth of ∞ from the May 31st total of 0 shares. Based on an average daily volume of 838,555 shares, the short-interest ratio is presently 1.3 days. Currently, 0.9% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Parabilis Medicines to a “hold” rating in a research note on Saturday, June 20th.

View Our Latest Stock Report on Parabilis Medicines

Parabilis Medicines Price Performance

PBLS stock traded up $1.82 during trading on Thursday, reaching $29.58. 302,352 shares of the stock traded hands, compared to its average volume of 1,035,604. Parabilis Medicines has a 52-week low of $24.51 and a 52-week high of $34.47.

Insider Transactions at Parabilis Medicines

In other news, major shareholder Guy Levy acquired 500,000 shares of Parabilis Medicines stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the purchase, the insider owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. This represents a 94.88% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan Sebulsky acquired 9,065 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $26.49 per share, for a total transaction of $240,131.85. Following the acquisition, the director directly owned 30,000 shares of the company’s stock, valued at approximately $794,700. The trade was a 43.30% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 530,000 shares of company stock valued at $10,723,528.

Featured Articles

Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.